Asim V. Farooq, MD, University of Chicago Medical Center

home / authors / asim-v-farooq-md-university-of-chicago-medical-center

Articles

Influencing Factors to Initially Targeting BCMA in MM

Influencing Factors to Initially Targeting BCMA in MM

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
February 1st 2021

Read More

Ongoing Approaches Toward Targeting BCMA

Ongoing Approaches Toward Targeting BCMA

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
February 1st 2021

Read More

Next Steps for Use of Belantamab in Clinical Practice

Next Steps for Use of Belantamab in Clinical Practice

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
February 1st 2021

Read More

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
January 25th 2021

Read More

Management of Ocular Events From DREAMM-2 Regimen

Management of Ocular Events From DREAMM-2 Regimen

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
January 25th 2021

Read More

DREAMM-2 Trial Regimen Safety Profile

DREAMM-2 Trial Regimen Safety Profile

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
January 18th 2021

Read More

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
January 18th 2021

Read More

The Rationale for Targeting BCMA in Multiple Myeloma

The Rationale for Targeting BCMA in Multiple Myeloma

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
December 18th 2020

Read More

Treatment Approach for R/R Multiple Myeloma

Treatment Approach for R/R Multiple Myeloma

Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University;Asim V. Farooq, MD, University of Chicago Medical Center;Natalie S. Callander, MD, University of Washington Carbone Cancer Center
December 18th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data